Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Tuberculosis (Edinb) ; 125: 102005, 2020 12.
Artigo em Inglês | MEDLINE | ID: mdl-33032092

RESUMO

Biofilm formed in vitro by mycobacteria has been associated with increased antibiotic tolerance as compared with planktonic cells. Cellulose has been identified as a component of DTT-exposed biofilms formed by M. tuberculosis. The celA1 gene of M. tuberculosis encodes a cellulase, which could affect the formation of biofilm by slow-growing mycobacteria. In this work, the celA1 gene of M. tuberculosis was cloned into the integrative pMV361 plasmid and then transformed into M. bovis BCG Pasteur to produce BCG:celA1, to have celA1 expressed from the strong promoter hsp60. We compared planktonic and biofilm growth, possible presence of CelA1 in whole protein extracts, quantitated biofilm, presence of monosaccharides, and bacillary burden in lungs after aerosol infection in BALB/c mice. Differences in the appearance of the surface pellicle and of the biofilm attached to the substrate were observed. In biofilms, we observed a significant decrease of glucosamine in BCG:celA1 compared with BCG:pMV361. Finally, BCG:celA1 had lower viable bacteria than the BCG:pMV361 strain after 24 h and 3 weeks post-infection, but no difference was found at 9 weeks post-infection.


Assuntos
Vacina BCG/farmacologia , Biofilmes/crescimento & desenvolvimento , Regulação Bacteriana da Expressão Gênica , Glucosamina/metabolismo , Mycobacterium tuberculosis/genética , Elastase Pancreática/genética , Tuberculose Pulmonar/microbiologia , Adjuvantes Imunológicos/farmacologia , Animais , Biofilmes/efeitos dos fármacos , DNA Bacteriano/genética , Modelos Animais de Doenças , Feminino , Pulmão/microbiologia , Camundongos , Camundongos Endogâmicos BALB C , Mycobacterium tuberculosis/efeitos dos fármacos , Mycobacterium tuberculosis/crescimento & desenvolvimento , Elastase Pancreática/biossíntese , Tuberculose Pulmonar/tratamento farmacológico
2.
BMC Microbiol ; 16(1): 290, 2016 Dec 12.
Artigo em Inglês | MEDLINE | ID: mdl-27955621

RESUMO

BACKGROUND: Pharmaceutical industry demands innovation for developing new molecules to improve effectiveness and safety of therapeutic medicines. Preclinical assays are the first tests performed to evaluate new therapeutic molecules using animal models. Currently, there are several models for evaluation of treatments, for dermal oedema or infection. However, the most common or usual way is to induce the inflammation with chemical substances instead of infectious agents. On the other hand, this kind of models require the implementation of histological techniques and the interpretation of pathologies to verify the effectiveness of the therapy under assessment. This work was focused on developing a quantitative model of infection and oedema in mouse pinna. The infection was achieved with a strain of Streptococcus pyogenes that was inoculated in an injury induced at the auricle of BALB/c mice, the induced oedema was recorded by measuring the ear thickness with a digital micrometer and histopathological analysis was performed to verify the damage. The presence of S. pyogenes at the infection site was determined every day by culture. RESULTS: Our results showed that S. pyogenes can infect the mouse pinna and that it can be recovered at least for up to 4 days from the infected site; we also found that S. pyogenes can induce a bigger oedema than the PBS-treated control for at least 7 days; our results were validated with an antibacterial and anti-inflammatory formulation made with ciprofloxacin and hydrocortisone. CONCLUSIONS: The model we developed led us to emulate a dermal infection and allowed us to objectively evaluate the increase or decrease of the oedema by measuring the thickness of the ear pinna, and to determine the presence of the pathogen in the infection site. We consider that the model could be useful for assessment of new anti-inflammatory or antibacterial therapies for dermal infections.


Assuntos
Modelos Animais de Doenças , Pavilhão Auricular/efeitos dos fármacos , Pavilhão Auricular/microbiologia , Edema/tratamento farmacológico , Dermatopatias Bacterianas/tratamento farmacológico , Infecções Estreptocócicas/tratamento farmacológico , Streptococcus pyogenes/fisiologia , Animais , Antibacterianos/uso terapêutico , Anti-Inflamatórios/uso terapêutico , Avaliação Pré-Clínica de Medicamentos/métodos , Pavilhão Auricular/patologia , Edema/microbiologia , Edema/patologia , Feminino , Camundongos , Camundongos Endogâmicos BALB C , Dermatopatias Bacterianas/microbiologia , Dermatopatias Bacterianas/patologia , Infecções Estreptocócicas/microbiologia , Infecções Estreptocócicas/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA